Drug profile · INN
brigatinib
ALUNBRIG
brigatinib (ALUNBRIG) is a alk tyrosine kinase receptor inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — brigatinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 15
- Data quality
- 0.89
Quick answer
brigatinib (ALUNBRIG) is a alk tyrosine kinase receptor inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
ALK tyrosine kinase receptor inhibitor
Primary target: ALK tyrosine kinase receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is brigatinib?
brigatinib (ALUNBRIG) is a alk tyrosine kinase receptor inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for brigatinib?
ALUNBRIG is a marketed brand name for brigatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brigatinib?
brigatinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.